Precigen has been granted a patent for a method of treating Friedreich’s Ataxia by administering a composition containing an AAV vector encoding human frataxin. The method targets symptoms like loss of coordination in the arms and legs through various administration routes. GlobalData’s report on Precigen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Precigen, Cancer treatment biomarkers was a key innovation area identified from patents. Precigen's grant share as of May 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Gene therapy for friedreich's ataxia using aav vector
A recently granted patent (Publication Number: US11998618B2) discloses a method for treating symptoms of Friedreich's Ataxia by administering a composition comprising an adeno-associated viral (AAV) vector encoding human frataxin. The method involves intrathecal (IT) administration, intracerebroventricular (ICV) administration, intraparenchymal administration, intracerebellar administration, or a combination thereof. The frataxin is expressed in specific regions of the subject's body at levels greater than 25% of normal levels, with the AAV vector being an AAV5 vector in some instances.
Furthermore, the patent describes a method for increasing frataxin levels in subjects with frataxin deficiency by administering an AAV vector encoding human frataxin. The frataxin produced should be at least 25% of normal levels. The method involves similar modes of administration as the previous claim. Additionally, a method for treating Friedreich's Ataxia symptoms using a pharmaceutical formulation containing the AAV vector and phosphate buffer solution is detailed. The frataxin produced should be at a level sufficient to treat the symptoms, with the administration routes mirroring those mentioned earlier. The patent also specifies the range of AAV vector doses to be administered to the subject.
To know more about GlobalData’s detailed insights on Precigen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
